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ABSTRACT 
The Extracorporeal Treatments in Poisoning (EXTRIP) Workgroup conducted a systematic 
literature review using a standardized process to develop evidence-based recommendations on the 
use of extracorporeal treatment (ECTR) in patients with phenytoin poisoning. The authors reviewed 
all articles, extracted data, summarized findings, and proposed structured voting statements 
following a pre-determined format. A two-round modified Delphi method was used to reach a 
consensus on voting statements, and the RAND/UCLA Appropriateness Method was employed to 
quantify disagreement. 51 articles met inclusion criteria. Only case reports, case series, and 
pharmacokinetic studies were identified yielding a very low quality of evidence. Clinical data from 
31 patients and toxicokinetic grading from 46 patients were abstracted. The Workgroup concluded 
that phenytoin is moderately dialyzable (Level of evidence = C) despite its high protein binding and 
made the following recommendations:  ECTR would be reasonable in selected cases of severe 
phenytoin poisoning, (Neutral recommendation, 3D). ECTR is suggested if prolonged coma is 
present or expected (2D) and it would be reasonable if prolonged incapacitating ataxia is present or 
expected (3D). If ECTR is used, it should be discontinued when clinical improvement is apparent 
(1D).  The preferred ECTR modality in phenytoin poisoning is intermittent hemodialysis (1D), but 
hemoperfusion is an acceptable alternative if hemodialysis is not available (1D). In summary, 
phenytoin appears to be amenable to extracorporeal removal. However, because of the low 
incidence of irreversible tissue injury or fatality related to phenytoin poisoning, and the relatively 
limited effect of ECTR on phenytoin removal, the Workgroup proposed the use of ECTR only in 
very select patients with severe phenytoin poisoning. 
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INTRODUCTION 
The Extracorporeal Treatments In Poisoning (EXTRIP) workgroup is composed of 
international experts representing diverse specialties and professional societies (Item S1) to provide 
recommendations on the use of extracorporeal treatments (ECTRs) in poisoning (www.extrip-
workgroup.org). The rationale, background, objectives, methodology, and its initial 
recommendations have been published previously.1-13 We present a systematic literature review and 
evidence-based recommendations for the use of ECTR in phenytoin poisoning. 
 
Pharmacology and Toxicokinetics 
Phenytoin is a hydantoin derivative that is used as a first-line agent in the control of tonic-
clonic and psychomotor seizures, and the prevention and treatment of seizures associated with 
neurosurgery.14-16 The main site of action of phenytoin is the motor cortex, where it stabilizes 
transmembrane flux of ions and reduces post-tetanic potentiation of synapses.14 Specifically, 
phenytoin inhibits sodium channels by reducing their capacity for recovery after inactivation.14,17 
Phenytoin also increases brain concentrations of gamma-aminobutyric acid (GABA), which has an 
inhibitory action in the cerebral cortex.14,15 
Phenytoin has a molecular mass of 252 Da, and it binds extensively to plasma proteins 
(binding = 90%), a percentage that stays unchanged after overdose18,19 but decreases slightly to 75-
80% in patients with kidney failure, hypoalbuminemia or cytochrome P450 (CYP) 2C9 genetic 
polymorphism.20 The unbound or "free" form is responsible for its clinical and toxicological 
effects.21,22 The reported time to peak plasma concentrations in therapeutic dosing is 1.5 to 3 hours 
for standard formulations and 4 to 12 hours for extended-release formulations. However, oral 
absorption of phenytoin is slow and variable, and can be delayed and unpredictable during 
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overdose. Peak plasma concentrations have been observed up to 96 hours after ingestion in the 
overdose setting.23-25 
Phenytoin had a volume of distribution of 0.6-0.8 L/kg, and is predominantly metabolized 
by the CYP enzyme system to inactive metabolites. The drug exhibits Michaelis-Menten kinetics; 
as such, increased doses may produce a larger than expected increase in plasma concentrations and 
prolonged elimination.14,21,26 Less than 1% of phenytoin is eliminated unchanged in urine, although 
its metabolites, including 5-(p-hydroxyphenyl)-5-phenylhydantoin (HPPH), are renally excreted. At 
therapeutic concentrations, phenytoin’s endogenous clearance is 23 mL/min27 and its apparent 
elimination half-life is approximately 22 hours (range 7 to 42 hours).14,21 In overdose, the 
elimination half-life increases; in one case it was reported to be as long as 103 hours.28 This 
explains why massive phenytoin ingestions may lead to prolonged toxicity and extended hospital 
stays. The physicochemical characteristics and pharmacokinetic properties of phenytoin are 
presented in Table 1. 
 
Overview of Phenytoin Poisoning 
US Poison Control Centers documented 2,850 phenytoin exposures in 2013, 528 of which 
had a clinical outcome defined as moderate outcome or worse, including one fatality.29 Oral 
overdose is characterized by cerebellar and vestibular effects including multi-directional nystagmus, 
dizziness, nausea, vomiting and ataxia.30,31 Severe overdose may result in coma and marked 
respiratory depression.30,31 To our knowledge, there is no previously published literature on the 
frequency of clinical effects for phenytoin overdoses. In response, we performed a search in the 
National Poison Data System from 2000 to 2014 for single substance phenytoin exposures, coded 
with a serious outcome (major effects or fatalities).32 Of the 734 retrieved cases, respiratory arrest 
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was reported in 3.1%, respiratory depression in 5.7%, coma in 16.1% and ataxia in 25.1%. The 
other most common signs and symptoms include seizures (44.1%), drowsiness/lethargy (39%), 
confusion (23.2%), nystagmus (17.8%), agitation/irritable (15.4%), hypotension (12.5%) and 
slurred speech (11.4%). Cardiac arrest was present in 3.5% of the cases and 29 patients died. 
Mortality or irreversible injury following phenytoin poisoning is infrequent but still 
reported.33-35 Intravenous overdose produces similar systemic effects to oral overdose, but 
cardiotoxicity, including hypotension, bradycardia, dysrhythmias and even asystole can occur.36,37 
These side effects are thought to be caused by the diluent (propylene glycol) rather than phenytoin 
itself.38,39 
Fosphenytoin, the intravenous prodrug of phenytoin, is designed with an extra phosphate 
linkage enhancing its water solubility. It comes as an injection, dissolved in sterile water and 
tromethamine buffer. In vivo, fosphenytoin is converted into phenytoin by losing the phosphate 
group. Though there is limited information on the toxicity of fosphenytoin, data from US poison 
centers from 2000 to 2014 on 208 single substance fosphenytoin exposures showed the most 
common symptoms including seizures (22.6%), drowsiness/lethargy (22.6%), no symptoms 
(17.3%), hypotension (14.9%), other (13.0%), ataxia (11.1%), agitated/irritable (9.1%), confusion 
(8.2%), vomiting (8.2%) and nystagmus (7.7%).32 In the 25 cases classified as serious (major 
effects or death), seizures remained the most common symptom at 44.0% followed by hypotension 
(32.0%), bradycardia (24%), and respiratory arrest (20%). Cardiac arrest was noted in 12.0% of 
serious cases. Case reports demonstrate that the most serious, acute complication of massive IV 
fosphenytoin overdoses is cardiovascular in nature (hypotension, bradydysrhythmias, conduction 
disturbances and even asystole). The signs and symptoms of a classic phenytoin poisoning (coma, 
ataxia, drowsiness, seizures) manifest as the toxicity progresses.40-45 
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The onset of symptoms usually occurs within minutes of intravenous administration and 
within 1 to 2 hours of ingestion, although the latter can be delayed or prolonged for up to a week 
due to prolonged absorption and saturable metabolism. Factors on admission that correlate with 
length of stay include disorientation and unarousability, concurrent phenothiazine usage and liver 
disease,46 while morbidity is correlated to ataxia.47 While therapeutic concentrations of total plasma 
phenytoin are reported to be 10-20 mcg/mL, free phenytoin concentrations (1-2 mcg/mL 
therapeutic; > 5 mcg/mL toxic) are more accurate in predicting clinical effects.48 However, there is 
little correlation between the phenytoin concentration at presentation and the severity of toxicity or 
length of stay.47 
The management of patients with phenytoin toxicity is largely supportive, including airway 
protection and correction of hypotension with intravenous fluids. Advanced cardiac life support 
guidelines should be followed when indicated. Gastrointestinal decontamination (e.g., single dose 
activated charcoal) should be given if the patient presents shortly after ingestion and has no 
contraindications, although there is no evidence that this alters the clinical course.49 There are no 
antidotes available to reverse phenytoin’s effects. While multiple-dose activated charcoal (MDAC) 
increases elimination of phenytoin,50-52 the data are conflicting regarding the improvement of 
clinical outcome in phenytoin overdose. In some studies MDAC failed to demonstrate a beneficial 
effect on time to resolution of phenytoin toxicity,53-55 while in other studies MDAC seems to 
improve the clinical course.56 For the moment, MDAC is not routinely recommended for the 
treatment of phenytoin ingestions,57 but may be considered in selected cases.58,59 Current toxicology 
resources do not routinely recommend ECTR for phenytoin poisoning, claiming unproven benefit 
on clinical outcomes.60-62 
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METHODS 
A Predetermined methodology, incorporating recommendations from The Appraisal of 
Guidelines for Research and Evaluation (AGREE)63 and Grading of Recommendation Assessment, 
Development and Evaluation (GRADE),64 was used and is described in detail elsewhere.2 The 
primary literature search was conducted on July 12th 2012 in Medline, Embase and Cochrane 
library (Review and Central). 
The search strategy was: [phenytoin OR dilantin] AND [toxicity OR poison* OR 
intoxication OR overdos*] AND [hemoperfusion OR haemoperfusion OR hemofiltration OR 
haemofiltration OR hemodialysis OR haemodialysis OR hemodiafiltration OR haemodiafiltration 
OR dialysis OR plasmapheresis OR plasma exchange OR exchange transfusion OR CRRT OR 
renal replacement therapy]. 
A manual search of conference proceedings of the European Association of European 
Association of Poisons Centres and Clinical Toxicologists (EAPCCT) and the North 
American Congress of Clinical Toxicology (NACCT) annual meetings (2002-2014), and Google 
Scholar was performed, as well as the bibliography of each article obtained during the literature 
search. 
A subgroup of EXTRIP completed the literature search, reviewed each article, extracted 
data and summarized findings. The level of evidence assigned to each clinical recommendation 
(Table 2) and dialyzability were determined based on established criteria.2 The potential benefits of 
the procedure were weighed against its cost, availability, related complications, and alternative 
treatments. All this information was submitted to the entire workgroup for consideration, along with 
structured voting statements based on a pre-determined format. 
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The strength of recommendations was evaluated by a two-round modified Delphi method 
for each proposed voting statement and a RAND/UCLA Appropriateness Method was used to 
quantify disagreement between voters, as previously described.2,65  Anonymous votes with 
comments were sent to the epidemiologist who then compiled and returned a summary to each 
participant. The workgroup met in person to exchange ideas and debate statements. A second vote 
was later conducted and these results were used in determining the core EXTRIP recommendations. 
The literature search was updated on November 15th 2014 using the methodology described above; 
new articles and the updated data summary were submitted to every participant who then updated 
their votes. 
 
RESULTS 
Results of the literature search are presented in Figure 1. A total of 546 articles were 
identified after removal of duplicates. In the final analysis, 51 studies were included for qualitative 
analysis: 30 case-reports or case-series (31 patients),18,19,33,35-37,66-89 17 pharmacokinetic studies (54 
patients),90-106 1 animal experiment,107 and 3 in vitro studies.108-110 No randomized-controlled trial 
(RCT) or observational studies were identified. 
 
Clinical Outcomes 
The evidence of a clinical effect of ECTR in phenytoin poisoning is comprised only of case 
reports and case series, which are inherently anecdotal, limited by a lack of controls, and susceptible 
to publication bias. Therefore, the quality of the evidence for all recommendations was graded as 
very low. 
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Clinical data from 30 reports and 31 patients were retrieved; the first reported case of ECTR 
was published in 1958 when hemodialysis was used to treat a boy poisoned with phenytoin.66 An 
aggregate description of clinical outcomes of reported cases is presented in Table 3. The average 
phenytoin ingestion and peak total concentration were 6.8 grams and 69.8 mcg/mL, respectively. 
The majority of patients presented with some level of impaired consciousness, and most reported 
cases were treated using either hemodialysis or hemoperfusion. 
In the studied cohort, most patients experienced some improvement during or shortly after 
ECTR, which was occasionally dramatic when using an efficient ECTR.19,71,77,79,87 Conversely, 
some patients experienced no apparent benefit from ECTR and developed a chronic protracted 
course or long-term sequelae.33,35,66,80,84 In others, incapacitating ataxia was still present one week 
after exposure.70,81 Although the natural history of severely poisoned patients not treated with 
ECTR suggests survival,111,112 irreversible neurological conditions may incur in those most at 
risk.23-25 In our cohort, survival was noted in some patients who reportedly ingested 10 grams or 
greater,33,67,69,71,84 and who had peak total phenytoin concentrations over 90 mcg/mL.33,35,66,70,75,87,88 
Complications associated with ECTR included thrombocytopenia after hemoperfusion,18,88 and 
peritonitis following peritoneal dialysis that led to death.74 The other fatality appeared unrelated to 
phenytoin toxicity and followed bowel infarction.86 
 
Dialyzability 
Phenytoin is a small molecule (252 Da) and has a small volume of distribution of 0.6 to 0.8 
L/kg.18,19,27 However, because of its extensive binding to plasma proteins (90%), hemoperfusion 
(HP) and therapeutic plasma exchange (TPE) would theoretically be most likely to efficiently 
remove phenytoin. TPE can readily remove phenytoin from the vascular compartment, albeit at a 
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slow rate; on average TPE removes 5-10% of total body load of phenytoin during a single 2-3 hour 
exchange93,95,99,102 and can provide clearances up to 20 mL/min (Table 4).78,113 Initial clearances 
with charcoal HP surpass this range but are subsequently limited by saturation of the column, which 
usually occurs within 2 hours.72,114 Although some sorbent adsorption columns have been tested in 
vitro, their application in clinical practice is unknown.109 
Historical reports suggest a lack of an effect of diffusive techniques including intermittent 
hemodialysis (HD) because of phenytoin's significant protein binding.36,67,71,76,90,92,94 However, 
encouraging results have been shown with high-efficiency filters,110 especially in patients 
presenting with conditions known to reduce protein binding (e.g., hypoalbuminemia, kidney 
disease); clearance may exceed 100 mL/min in uremic patients.103 Clearances are inferior but 
nevertheless considerable in patients who have normal protein binding, although the workgroup 
acknowledged that additional study is required to confirm this.19,86 One report describes a patient 
who ingested 3.6 grams of phenytoin who was treated with HD.19 A total of 547 mg of phenytoin 
was extracted in approximately 6 hours. Overall, the aggregate ECTR clearance (Table 4) and the 
toxicokinetic grading of all patients (Table 5) demonstrate the superiority of both HP and high-
efficiency HD over all other techniques. The advantages of HP over HD for phenytoin removal are 
less clear; in patients who underwent both techniques, HP was superior to HD in one report,82 and 
inferior in the other.86 The addition of a charcoal column in series after a dialysis filter appears to 
enhance clearance of both HP or HD alone, but requires further study.86 
Supplementation of albumin into the dialysate does not appear to substantially enhance 
removal of phenytoin.74,110 The data on other liver support therapies, like molecular adsorbent 
recirculating systems (MARS), are limited: in one case, the apparent phenytoin elimination half-life 
during MARS was 8.4 h, which is not shorter than what can be achieved with more conventional 
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and less expensive alternatives.37 Further studies are needed to confirm the role of liver support 
therapies, especially considering their cost. Other ECTRs show limited phenytoin clearance (< 10 
mL/min)113 including exchange transfusion (ET),76 peritoneal dialysis (PD),68,69 and continuous 
renal replacement therapy (CRRT)100,104 and are therefore of very limited use in phenytoin 
poisoning. 
In summary, the best reported clearances that can be sustained are with HD, possibly in-
series with a charcoal cartridge. Based on the criteria established previously,9 the dialyzability of 
phenytoin is "slightly dialyzable" or "not dialyzable" for less efficient techniques like ET, PD, 
CRRT, and conventional HD techniques using less efficient cuprophane membranes. Phenytoin is 
"slightly" to "moderately dialyzable" with TPE and "moderately dialyzable" to "dialyzable" for HP, 
high-efficiency HD, and liver support therapies, especially if the patient presents with a condition 
that is associated with decreased protein binding (e.g., hypoalbuminemia, malnutrition, kidney 
disease). The workgroup preferred a conservative grading and therefore agreed with the following 
statement: Phenytoin is moderately dialyzable (level of evidence = C). Again, it was acknowledged 
that more studies using contemporary ECTR technology and parameters as well as performing more 
complete toxicokinetic measurements, especially quantification of removal in effluent fluid,9 are 
needed to support this observation. 
There are no studies that specifically compare ECTR to MDAC with respect to enhanced 
elimination of phenytoin. In three case reports, ECTR appeared superior, although the toxicokinetic 
data are relatively incomplete and cannot be reliably interpreted.19,33,84 
 
RECOMMENDATIONS 
An executive summary of the recommendations is provided in Box 1. 
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1. General statement regarding use of ECTR 
• ECTR would be reasonable in selected cases of severe phenytoin poisoning (Neutral 
recommendation - 3D) 
 
Rationale: Phenytoin is a widely used pharmaceutical, and toxicity following an acute ingestion or 
in therapeutic dosing is common.29 Life-threatening symptoms are infrequent and usually resolve 
completely with appropriate supportive treatment. No antidotes currently exist to reverse the toxic 
effects of phenytoin and the use of MDAC remains controversial.50,55 In severe cases, incapacitating 
and prolonged ataxia may occur, which can progress to stupor and coma. ECTR not only removes 
phenytoin from the blood compartment, but also simultaneously from the CSF, its toxic 
compartment.83 This may be the reason why several reports describe a marked improvement in the 
patients’ levels of consciousness during or following ECTR. 
Despite the absence of robust evidence, the workgroup considered the following arguments 
in evaluating the risks and benefits of ECTR in phenytoin poisoning: the risk of prolonged coma 
with mechanical ventilation is not negligible; complications associated with ECTR are infrequent 
and usually mild; high efficiency intermittent ECTR can achieve rapid and substantial removal of 
phenytoin; and there is anecdotal evidence of clinical improvement following ECTR. Conversely, 
the mortality and long-term disability associated with phenytoin poisoning is very low; the cost of 
ECTR is not negligible, especially if the patient requires a transfer to another facility, and there is a 
theoretical risk of precipitating a seizure if phenytoin concentrations are abruptly lowered with 
ECTR in a patient with a known seizure disorder. 
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Given the lack of significant end-organ damage, the primary rationale for ECTR in 
phenytoin poisoning is to attenuate potential morbidity rather than to decrease related mortality. 
Several participants postulated that ECTR might decrease mechanical ventilation time, ICU length 
of stay and overall length of stay, which will in turn lessen financial cost; however, this effect 
would have to be weighed against the inherent risks and costs of ECTR mentioned above. 
Unfortunately, there are no cost-benefit studies that confirm or refute this hypothesis. Other 
participants believed that active supportive measures are sufficient. Taking into account the relative 
uncertainty concerning the toxicokinetic results detailed above, potential clinical benefit, risks, and 
the economic considerations and resource utilization, the workgroup proposed a neutral 
recommendation on the use of ECTR in severe phenytoin poisoning, meaning that ECTR would be 
reasonable in the right context. Twelve participants voted for ECTR, 8 participants supported a 
neutral position, and 7 voted against ECTR (median vote = 5, disagreement index < 1). Therefore, 
ECTR should probably only be considered in those patients that present following a massive 
ingestion who exhibit life-threatening toxicity and/or are expected to have very prolonged 
symptoms and in whom ECTR is considered to be safe. This case can be made for ECTR in a 
profoundly symptomatic patient, who by virtue of phenytoin’s zero order kinetics, is likely to have 
a prolonged hospital stay. The opposite decision can be made for a moderately symptomatic patient 
needing a transfer to another center to receive ECTR, where supportive management can be 
preferred over ECTR. In other words, ECTR can be considered in selected cases where the potential 
benefit seems to outweigh the risks. Further study is needed to determine the place of ECTR in the 
management of phenytoin toxicity in the subpopulation with decreased protein binding of phenytoin 
(e.g., kidney failure, hypoalbuminemia). 
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2. Indications for ECTR 
• ECTR is suggested if prolonged coma is present or expected (2D) 
• ECTR would be reasonable if prolonged incapacitating ataxia is present or expected 
(3D) 
• We recommend NOT to perform ECTR solely based on a suspected dose of phenytoin 
ingested (1D) 
• We recommend NOT to perform ECTR solely based on serum phenytoin 
concentration (1D) 
 
Rationale: The workgroup proposed that indications for ECTR initiation in any poisoning should be 
based on criteria that include exposure route (e.g., ingestion, intravenous), measurement of toxin in 
body fluids, technical examinations, and clinical symptoms and signs. 
The workgroup agreed that there were too many uncertainties related to the dose of 
phenytoin ingested to initiate ECTR based on this information alone, certainly for a toxin that 
usually results in minimal or no long-term damage. The preferred management for patients 
presenting after an acute phenytoin exposure includes supportive measures, proper gastrointestinal 
decontamination with single dose activated charcoal and possibly MDAC. If the ingestion history is 
confirmed and the clinician suspects that major toxicity might ensue, then early communication 
with a toxicologist and nephrologist for consideration of possible ECTR may be warranted. This 
may be impossible in the event of IV overdose, given the rapid absorption and distribution (within 
minutes) and ensuing toxicity from the diluent. 
Monitoring of serum phenytoin concentrations can confirm an acute exposure and may be 
available in a time frame short enough to guide clinical decisions. Nevertheless, the workgroup 
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suggested that the decision to initiate ECTR should be more dependent on symptomatology than on 
an arbitrary serum phenytoin concentration threshold. Prophylactic ECTR (i.e., ECTR before the 
appearance of symptoms) can be considered in poisons where irreversible or life-threatening 
clinical toxicity is expected (e.g., methanol, theophylline) but the workgroup did not endorse this 
approach for phenytoin. 
Signs and symptoms following phenytoin poisoning are primarily neurologic. As stated 
earlier, phenytoin poisonings generally have a good prognosis and should be managed with 
supportive therapy. Coma in phenytoin poisoning is not due to a structural CNS lesion and it is also 
not considered life threatening in and of itself. However, coma following phenytoin poisoning may 
be prolonged and might necessitate protracted mechanical ventilation and ICU stays, warranting 
consideration of the risks of complications of prolonged intubation and/or intensive care treatment. 
For that reason, ECTR was not strongly recommended for coma by the workgroup. ECTR seems 
indicated only for an expected prolonged coma with the rationale to attenuate coma-induced 
complications and resource utilization. 
There was less support for ECTR in prolonged incapacitating ataxia. These patients can 
easily be managed in a non-intensive care setting, and therefore would not use excessive resources, 
thus undermining the economic considerations. More benign symptoms like nystagmus did not 
warrant ECTR. 
Seizures may occur in phenytoin poisoning and are very difficult to differentiate from 
seizures in a patient with seizure disorder. Some participants advocated the use of alternative 
anticonvulsants instead of ECTR in these patients, while other participants drew attention to the risk 
of dialyzing not only phenytoin, but also other anticonvulsants in patients with seizure disorders. No 
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agreement was reached on the use of ECTR in a patient with phenytoin poisoning if multiple 
seizures occur. 
 
3. Cessation of ECTR 
• ECTR should be discontinued when clinical improvement is apparent (1D) 
 
Rationale: Because the recommendations for ECTR initiation are solely based on clinical 
symptoms, it is logical and reasonable to pursue ECTR until clear clinical improvement is present. 
Given the relatively modest clearances obtained with high-efficiency ECTRs, prolonged ECTR or a 
repeat session may be required. Phenytoin concentrations may rebound after ECTR, especially after 
a high-efficiency procedure.19,33,72,75,84 Although this is rarely a concern if caused by redistribution 
from deeper compartments, it may cause clinical morbidity if rebound is related to ongoing 
absorption, which has been reported as extensive in some cases.33 It is therefore proposed to 
monitor clinical status and phenytoin concentrations serially over 24 hours after ECTR to help 
assess the need for subsequent sessions. 
 
4. Choice of ECTR 
• Intermittent hemodialysis is the preferred ECTR in phenytoin poisoning (1D) 
• Intermittent hemoperfusion is an acceptable alternative if intermittent hemodialysis is 
not available (1D) 
 
Rationale: According to the workgroup, intermittent HD is the preferred modality of ECTR in 
phenytoin poisoning. This recommendation is supported by the following arguments: clearance of 
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phenytoin has increased dramatically with the use of high-flux synthetic membranes compared to 
less efficient cuprophane or polyacrylonitrile filters;103 intermittent HD is the most widely available 
modality of dialysis worldwide; more physicians and nurses are experienced with HD, with lesser 
risks of delay and uncertainty; the complication rate with HD appears favorable in comparison to 
HP, especially with regard to thrombocytopenia during HP, as described in some of the patients 
included in the cohort;18,73,88 the cost of HD favors it over HP. This is largely explained by the cost 
of monitoring and treating complications as well as the lower cost of dialysis filters versus charcoal 
cartridges, which need to be replaced regularly because of saturation of their adsorptive capacity. 
Based on the fact that phenytoin is highly protein bound, a more efficient membrane and the 
optimization of both blood flow and effluent (dialysate and/or ultrafiltration) flow will have 
relatively minor but nevertheless significant effects on phenytoin clearance and are 
recommended.91,100,110,115 
If HD is not available, the workgroup recommended HP as an acceptable and useful 
alternative, as there is reliable data on its efficacy. HD and HP can also be used simultaneously in 
series with some clinical benefit.86,87 Peritoneal dialysis, albumin dialysis, exchange transfusion 
(ET) and therapeutic plasma exchange would not offer comparable results to HD or HP and are 
currently not recommended by EXTRIP for phenytoin poisoning. Continuous techniques, offer 
markedly lower clearances and removal rates compared to intermittent techniques. 
 
CONCLUSION 
The EXTRIP workgroup presents its recommendations for extracorporeal treatments in 
phenytoin poisoning. The great majority of cases can be treated with supportive care that may 
include single or multiple dose activated charcoal. In patients in whom prolonged coma is present 
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or expected, ECTR  is suggested to accelerate elimination of phenytoin and to theoretically reduce 
ICU stay and its associated morbidity. The preferred choice of ECTR is high-efficiency intermittent 
hemodialysis. The workgroup advises to weigh the costs and risks associated with ECTR against 
the possible benefits in phenytoin toxicity and to individualize decisions to perform ECTR. 
.  
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Table 1.  Physicochemical and pharmacokinetic properties of phenytoin 
 
Molecular mass 252 Da 
Oral bioavailability 90% 
Protein binding 90% (70-80% in hypoalbuminemia) 
Volume of distribution 0.6-0.8 L/kg 
Therapeutic rangea 10-20 mcg/mL (39.6-79.2 µmol/L) 
Toxic ingestion ≥ 20 mg/kg 
Toxic plasma concentrations ≥ 20 mcg/mL (79 µmol/L) 
aTo convert units 1.0 mcg/mL = 3.96 µmol/L 
 
  
 23 
 
Table 2.  Strength of recommendation and level of evidence scaling for clinical outcomes 
 
Strength of recommendation 
(consensus-based) 
Level of evidence 
(based on GRADE system) 
 
Level 1 = Strong recommendation 
“We recommend…” 
The course of action is considered 
appropriate by the large majority of 
experts with no major dissension The 
panel is confident that the desirable 
effects of adherence to the 
recommendation outweigh the 
undesirable effects. 
 
Level 2 = Weak recommendation 
“We suggest…” 
The course of action is considered 
appropriate by the majority of experts 
but some degree of dissension exists 
amongst the panel. The desirable effects 
of adherence to the recommendation 
probably outweigh the undesirable 
effects. 
 
Level 3 = Neutral recommendation 
“It would be reasonable…” 
The course of action could be considered 
appropriate in the right context 
 
No recommendation 
No agreement was reached by the group 
of experts 
 
 
Grade A = High level of evidence 
The true effect lies close to our estimate of the 
effect 
 
Grade B = Moderate level of evidence 
The true effect is likely to be close to our 
estimate of the effect, but there is a possibility 
that it is substantially different  
 
Grade C = Low level of evidence 
The true effect may be substantially different 
from our estimate of the effect 
 
Grade D = Very low level of evidence 
Our estimate of the effect is just a guess, and it 
is very likely that the true effect is 
substantially different from our estimate of the 
effect 
Adapted from Lavergne V, Nolin TD, Hoffman RS, et al. The EXTRIP (EXtracorporeal 
TReatments In Poisoning) workgroup: guideline methodology. Clin Toxicol (Phila). 
2012;50(5):403-413. 
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Table 3. Aggregate clinical outcomes of the 31 overdose patients 
described in case reports or case series 
 
Demographics Age in years [mean (range)] 26.7 (0.1-77) 
Male (%) 63.3% 
Phenytoin 
exposure 
 
Amount ingested (grams)  6.8 (1-21.5) 
Peak total phenytoin conc [mean 
(range)] (mcg/mL) 
69.8 (15-200.7) 
Time from ingestion to  
presentation (hours) 
18.1 (1-120) 
Toxic 
symptoms (%) 
Altered consciousness 90.3% 
Seizure (one or more) 19.4% 
Respiratory failure 32.3% 
Dysarthria/ataxia 25.8% 
Other 
treatments (%) 
Mechanical ventilation 25.8% 
MDAC 9.7% 
ECTR (N) HD 7 
HP 7 
CRRT 0 
HP-HD 3 
TPE 3 
ET 1 
PD 6 
Liver support therapy (MARS) 1 
More than 1 ECTR 3 
Outcome (%) Sequelae 12.9% 
Death 6.5% 
 
HD, intermittent hemodialysis; HP, hemoperfusion; CRRT, continuous renal 
replacement therapy; HD-HP, intermittent hemodialysis and hemoperfusion 
in series; TPE, therapeutic plasma exchange; ET, exchange transfusion; PD, 
peritoneal dialysis; MARS, molecular adsorbent recirculating system. 
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Table 4.  Clearance of various ECTRs from accepted articles 
 
ECTR Patients 
Clearance (mL/min) 
References 
Average Range 
Conventional HD 10 16.7 6.5-42 71,90-92 
High efficiency HD 3 68.1 44.3-112 19,86,103 
Charcoal HP 4 28.8 18-42 72,73,83,86 
HD-HP 1 58.4  86 
TPE 14 18.5 7.8-43 75,78,80,81,93,95-99,102 
PD 6 3.3 0.2-10.6 36,68,69,74,76,94 
ET 1 3.1  76 
CRRT 4 6.5 0.9-13 100,104 
 
HD, intermittent hemodialysis; HP, hemoperfusion; HD-HP, intermittent hemodialysis 
and hemoperfusion in series; TPE, therapeutic plasma exchange; PD, peritoneal dialysis; 
ET, exchange transfusion; CRRT, continuous renal replacement therapies. 
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Table 5.  Toxicokinetic grading attributed to individual patients 
 
 Number of Patients Graded 
 
PD HP HD 
(conv) 
HD 
(high-eff) 
HD-HP 
(in series) 
CRRT TPE ET LST 
Dialyzable  2  2 1    1 
Moderately 
dialyzable 
 2  2   7   
Slightly 
dialyzable 1  5   2 7 1  
Not 
dialyzable 5  4   2 2   
 
PD, peritoneal dialysis; HP, hemoperfusion; HD (conv), conventional intermittent 
hemodialysis; HD (high-eff), high efficiency intermittent hemodialysis; HD-HP, 
intermittent hemodialysis and hemoperfusion in series; CRRT, continuous renal 
replacement therapy; TPE, therapeutic plasma exchange; ET, exchange transfusion; 
LST, liver support therapy. 
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Box 1.  Executive summary of recommendations 
 
General statement regarding use of ECTR 
• ECTR would be reasonable in selected cases of severe phenytoin poisoning (3D) 
 
Indications for ECTR 
• ECTR is suggested if prolonged coma is present or expected (2D)  
• ECTR would be reasonable if prolonged incapacitating ataxia is present or expected (3D)  
• We recommend NOT to perform ECTR solely based on suspected dose of phenytoin 
ingested (1D)  
• We recommend NOT to perform ECTR solely based on serum phenytoin concentration (1D)  
 
Cessation of ECTR 
• ECTR should be discontinued when clinical improvement is apparent (1D)  
 
Choice of ECTR 
• Intermittent HD is the preferred ECTR in phenytoin poisoning (1D)  
• Intermittent HP is an acceptable alternative if intermittent HD is not available (1D)  
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Figure legend 
 
Figure 1.  Summary of literature search on use of ECTR in phenytoin poisoning. 
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Figure 1. 
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488 records identified 
through EMBASE 
185 full-text articles 
assessed for eligibility 
546 records identified after duplicates removed 
51 studies included in qualitative synthesis 
(English = 44, French = 1, German = 3, Japanese = 2, Serbo-Croatian = 1) 
 
134 full-text articles 
excluded 
361 records excluded 546 records screened 
92 records identified 
through MEDLINE 
14 records identified 
by manual searching 
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Supplementary Material 
 
Item S1.  Represented Societies 
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Item S1.  Societies represented in EXTRIP 
American Academy of Clinical Toxicology 
American College of Emergency Physicians 
American College of Medical Toxicology 
American Society of Nephrology 
American Society of Pediatric Nephrology 
Asia Pacific Association of Medical Toxicology 
Australian and New Zealand Intensive Care Society 
Australian and New Zealand Society of Nephrology 
Brazilian Association of Poison Control Centers and Clinical Toxicologists 
Brazilian Society of Nephrology 
Brazilian Society of Toxicology 
Canadian Association of Poison Control Centres 
Canadian Association of Emergency Physicians 
Canadian Society of Nephrology 
Chinese College of Emergency Physicians 
Chinese Medical Doctor Association 
European Association of Poison Centres and Clinical Toxicologists 
European Renal Best Practice 
European Society of Emergency Medicine 
European Society of Intensive Care Medicine 
French Language Society of Resuscitation 
German Society of Nephrology 
International Pediatric Nephrology Association 
International Society of Nephrology 
Latin American Society of Nephrology and Hypertension 
National Kidney Foundation 
Pediatric Continuous Renal Replacement Therapy 
Pediatric Critical Care Medicine 
Quebec Association of Emergency Physicians 
Quebec Association of Specialists in Emergency Medicine 
Quebec Society of Nephrology 
Renal Association 
Society of Critical Care Medicine 
Spanish Clinical Toxicology Foundation 
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